Urufarma's success story has been characterized by strategic decisions.

In 1996, Urufarma decided to revamp its business and focus on manufacturing hormonal oral solids. This meant a significant investment in infrastructure, as well as acquiring the skills and knowledge to break into the business and soon become its leader.

The acquired knowledge and the applied technology have allowed Urufarma to access a diversity of markets, which required the certification of the company and its facilities in compliance with the Good Manufacturing Practices of the pharmaceutical industry.

In 2009, to meet the growing demand for hormonal products at a domestic and global scale, Urufarma decided to set in motion an important investment project consisting of a relocation of the oral solids manufacture. The new factory, inaugurated in May 2012, provides us the production capacity to meet those demands.

Investing in growth

We are constantly investing, as evidenced by the 20 million dollars invested in our new industrial facilities.

These facilities increase the manufacturing capacity of hormonal products, while enhancing the company's overall operational efficiency, in a work environment of optimum conditions for our staff and strict environmental care regulations.

The growth in production allows Urufarma to keep pace with the development of our clients and seek new markets.

Increased exports
Investments have a direct impact on the increase in exports, as we project reaching 15 million dollars in the next 3 years.

Urufarma |  Investing in growth
URUFARMA - INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos
URUFARMA - Ministerio de Salud Pública
URUFARMA - DIGEMID - Dirección General de Medicamentos, Insumos y Drogas
URUFARMA - Organización Mundial de la Salud